Wockhardt
Wockhardt Share Price Chart
Wockhardt last traded at ₹1,961.50 (2026-10-13). Over the past month the stock moved -11.6%, three months the stock moved +15.1%, year the stock moved +30.3%. Its closing range over 52 weeks is ₹1,176.90 – ₹2,329.80, with the latest close 15.8% below the high.
Closing prices up to 2026-10-13.
About Wockhardt
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Business Divisions: a) New Drug Discovery: [1] [2] The company’s New Drug Discovery programme focuses on developing novel antibiotics to address the growing threat of antimicrobial resistance (AMR) and unmet needs in treating MDR and XDR infections. It follows a “discovery-to-delivery” approach, advancing first-in-class and differentiated antibiotics from research and clinical development to commercialisation across India and inter national markets. During FY26, 5 novel antibiotics, including Emrok, Emrok O, Miqnaf, Zaynich, and Foviscu, completed Phase 3 development, while Odrate progressed to Phase 2. The portfolio covers infections including MRSA, ESBL-producing and carbapenem-resistant pathogens, pneumonia and complicated urinary tract infections. b) Branded Pharmaceuticals:[3] The company is engaged in the development, manufacturing, and marketing of finished formulations, biopharmaceuticals, branded generics, OTC, and prescription products across various therapeutic segments. Its key biopharmaceutical products include Glaritus, Wosulin, Wepox, and recombinant human insulin. It ranks among the Top 3 in around 20 products in the US, among theTop 5 generic companies in the UK, and as the largest ** generic company in Ireland’s hospital segment. c) Contract Manufacturing: [4] The company offers contract manufacturing services from product development to high-volume commercial manufacturing. Its full turnkey service is supported by experienced teams across development, technology transfer, manufacturing, quality assurance, regulatory affairs, logistics, engineering, and purchasing. d) Biosimilar: [5][6] The company focuses on developing and manufacturing biosimilar and bio better products, with diabetes as a key focus area. Its portfolio includes rapid, fast, and long-acting insulin formulations, available in vials and cartridges, along with patented insulin pens. It has applied for 118 biotech product patents globally and holds 57 patents in the biosimilar and bio-better development phase, out of which 23 patents are for the company’s insulin pen globally. In FY26, the company has obtained patents in 10 European countries for its new combination drug product. e) Vaccines:[7][8] The company manufactures vaccines across its UK and India facilities. Its Wrexham facility has manufactured the AstraZeneca-Oxford COVID-19 vaccine, and the company has partnered with the Serum Institute of India for vaccine manufacturing in the UK. Its Indian facilities are approved for vaccine manufacturing and exports of up to 1 Bn doses. f) API:[9] The company manufactures complex APIs and formulations and has developed 140+ US ANDAs and 60+ EU CTD dossiers, covering multiple dosage forms and niche products. It is also among the largest** manufacturers of Dextromethorphan HBr API globally and explores licensing opportunities across the US and Europe.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Wockhardt reported sales of ₹929.00 crore (+25.9%) and net profit of ₹107.00 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 929.00 | 192.00 | 21.00 | 107.00 | 6.52 |
| Mar 2026 | 965.00 | 225.00 | 23.00 | 164.00 | 10.22 |
| Dec 2025 | 888.00 | 177.00 | 20.00 | 61.00 | 3.63 |
| Sep 2025 | 782.00 | 178.00 | 23.00 | 82.00 | 4.80 |
| Jun 2025 | 738.00 | 72.00 | 10.00 | -108.00 | -5.54 |
| Mar 2025 | 743.00 | 64.00 | 9.00 | -45.00 | -1.54 |
| Dec 2024 | 721.00 | 128.00 | 18.00 | 20.00 | 0.86 |
| Sep 2024 | 809.00 | 110.00 | 14.00 | -16.00 | -1.43 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +7.4% | +2.9% | +6.1% | -0.1% | -3.3% | +23.2% | +29.9% | +25.9% |
| Operating profit growth | +52.8% | +245.9% | – | -20.9% | +61.8% | +38.3% | +251.6% | +166.7% |
| Net profit growth | – | – | – | – | – | +205.0% | – | – |
| EPS growth | – | – | – | – | – | +322.1% | – | – |
| OPM % | 14.0% | 18.0% | 9.0% | 10.0% | 23.0% | 20.0% | 23.0% | 21.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Wockhardt reported sales of ₹3,373.00 crore (+12.0%) and net profit of ₹199.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 3,373 | 652.00 | 19.00 | 199.00 | 13.11 |
| Mar 2025 | 3,012 | 393.00 | 13.00 | -57.00 | -2.89 |
| Mar 2024 | 2,798 | 91.00 | 3.00 | -472.00 | -30.18 |
| Mar 2023 | 2,651 | 102.00 | 4.00 | -621.00 | -38.80 |
| Mar 2022 | 3,230 | 298.00 | 9.00 | -279.00 | -16.94 |
| Mar 2021 | 2,708 | -63.00 | -2.00 | 688.00 | 47.64 |
| Mar 2020 | 2,844 | 119.00 | 4.00 | -43.00 | -4.81 |
| Mar 2019 | 3,566 | -38.00 | -1.00 | -217.00 | -13.52 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -9.4% | -20.2% | -4.8% | +19.3% | -17.9% | +5.5% | +7.6% | +12.0% |
| Operating profit growth | -2000.0% | – | -152.9% | – | -65.8% | -10.8% | +331.9% | +65.9% |
| Net profit growth | – | – | – | -140.6% | – | – | – | – |
| EPS growth | – | – | – | -135.6% | – | – | – | – |
| OPM % | -1.0% | 4.0% | -2.0% | 9.0% | 4.0% | 3.0% | 13.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Wockhardt.
Get Free AI Stock Analysis FREE →Latest News
-
Sun Pharma, Wockhardt: Pharma stocks lift Nifty Pharma 1.5%; key things to know
-
Sun Pharma, Wockhardt: Pharma stocks lift Nifty Pharma 1.5%; key things to know
-
Wockhardt Ltd Posts Q1 PAT of Rs 107 cr
-
Wockhardt Ltd Posts Q1 PAT of Rs 107 cr
-
Wockhardt Ltd spurts 1.84%, rises for third straight session - business-standard.com
-
Wockhardt Ltd spurts 1.84%, rises for third straight session - business-standard.com
-
Wockhardt Ltd spurts 1.84%, rises for third straight session - Business Standard
-
Wockhardt Ltd Hits Intraday High with 7.81% Surge on 3 June 2026
-
Wockhardt Ltd shares plunge over 8% amid profit booking pressure after a 50% rally
-
Wockhardt Ltd shares plunge over 8% amid profit booking pressure after a 50% rally
Frequently Asked Questions
What is the share price of Wockhardt today?
Wockhardt shares were last quoted at ₹1,961.50 (-1.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Wockhardt?
Wockhardt has a price-to-earnings (P/E) ratio of 90.04 and a price-to-book (P/B) ratio of 7.30. The industry P/E is 53.33.
What is the 52-week high and low of Wockhardt?
The 52-week high of Wockhardt is ₹2,420.00 and the 52-week low is ₹1,086.80.
What is the market cap of Wockhardt?
The market capitalisation of Wockhardt is about ₹36,827.23 crore.
How did Wockhardt perform in its latest quarterly results?
In the latest quarter (Jun 2026), Wockhardt reported sales of ₹929.00 crore (+25.9%) and net profit of ₹107.00 crore, compared with the same quarter last year.
Is Wockhardt a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Wockhardt has a 3-year ROE of -1.00%, 3-year profit growth of 43.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Wockhardt?
Promoters hold about 49.08% of Wockhardt.
Which sector does Wockhardt belong to?
Wockhardt belongs to the Pharmaceuticals & Drugs sector.